US Stock MarketDetailed Quotes

Reviva Pharmaceuticals (RVPH)

Watchlist
  • 0.8500
  • -0.0240-2.75%
Close Apr 17 16:00 ET
  • 0.8700
  • +0.0200+2.35%
Post 20:01 ET
10.89MMarket Cap-0.16P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Reviva Pharmaceuticals (RVPH) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
-34.41%20.2M
-43.37%3.56M
-52.38%4.03M
-25.30%6.07M
-17.47%6.54M
-22.04%30.8M
-34.67%6.28M
-26.82%8.46M
-28.28%8.13M
13.42%7.92M
Selling and administrative expenses
7.60%8.49M
13.48%1.82M
18.34%1.9M
-7.74%2.35M
13.39%2.42M
-2.38%7.89M
6.05%1.6M
-19.46%1.6M
-17.34%2.55M
42.50%2.14M
-General and administrative expense
7.60%8.49M
13.48%1.82M
18.34%1.9M
-7.74%2.35M
13.39%2.42M
-2.38%7.89M
6.05%1.6M
-19.46%1.6M
-17.34%2.55M
42.50%2.14M
Research and development costs
-48.89%11.71M
-62.85%1.74M
-68.92%2.13M
-33.30%3.72M
-28.88%4.11M
-27.09%22.91M
-42.26%4.68M
-28.35%6.86M
-32.36%5.58M
5.47%5.78M
Operating profit
34.41%-20.2M
43.37%-3.56M
52.38%-4.03M
25.30%-6.07M
17.47%-6.54M
22.04%-30.8M
34.67%-6.28M
26.82%-8.46M
28.28%-8.13M
-13.42%-7.92M
Net non-operating interest income expense
-13.10%297.97K
248.76%148.93K
17.45%56.5K
-78.11%18.05K
-56.08%74.49K
-5.98%342.87K
-1.26%42.7K
-43.98%48.1K
-8.71%82.46K
21.71%169.61K
Non-operating interest income
-13.84%311.37K
202.26%143.31K
11.00%59.1K
-73.92%22.85K
-50.25%86.11K
-9.30%361.37K
-16.17%47.41K
-41.97%53.25K
-15.01%87.61K
17.74%173.1K
Non-operating interest expense
-27.55%13.4K
-219.30%-5.62K
-49.38%2.61K
-6.91%4.8K
233.24%11.62K
-45.15%18.5K
-64.61%4.71K
-12.79%5.15K
-59.61%5.15K
-54.45%3.49K
Other net income (expense)
-89.93%56.05K
452.92%45.32K
-171.12%-34.59K
-95.23%9.28K
-88.95%36.05K
630.52%556.73K
-105.94%-12.84K
-66.29%48.63K
142.67%194.65K
9,787.74%326.28K
Gain on sale of security
-87.60%89.01K
500.02%44.51K
-138.46%-27.82K
-94.44%11.13K
-86.59%61.19K
400.00%717.65K
-116.67%-11.13K
-48.00%72.32K
143.90%200.27K
4,000.10%456.18K
Other non- operating income (expenses)
79.52%-32.96K
147.20%809
71.40%-6.77K
67.09%-1.85K
80.64%-25.15K
-219.84%-160.92K
-101.15%-1.71K
-556.05%-23.69K
-29,484.21%-5.62K
-796.19%-129.89K
Income before tax
33.62%-19.85M
46.20%-3.36M
52.09%-4.01M
23.01%-6.05M
13.45%-6.43M
23.81%-29.9M
33.17%-6.25M
26.19%-8.37M
32.89%-7.85M
-8.43%-7.43M
Income tax
-3.20%18.89K
-39.11%2.88K
2.84K
7.70%7.95K
-29.52%5.21K
15.13%19.51K
203.30%4.73K
0
14.75%7.39K
148.35%7.4K
Net income
33.60%-19.86M
46.20%-3.37M
52.06%-4.01M
22.98%-6.05M
13.46%-6.43M
23.79%-29.92M
33.09%-6.26M
26.27%-8.37M
32.87%-7.86M
-8.49%-7.43M
Net income continuous Operations
33.60%-19.86M
46.20%-3.37M
52.06%-4.01M
22.98%-6.05M
13.46%-6.43M
23.79%-29.92M
33.09%-6.26M
26.27%-8.37M
32.87%-7.86M
-8.49%-7.43M
Minority interest income
Net income attributable to the parent company
33.60%-19.86M
46.20%-3.37M
52.06%-4.01M
22.98%-6.05M
13.46%-6.43M
23.79%-29.92M
33.09%-6.26M
26.27%-8.37M
32.87%-7.86M
-8.49%-7.43M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
33.60%-19.86M
46.20%-3.37M
52.06%-4.01M
22.98%-6.05M
13.46%-6.43M
23.79%-29.92M
33.09%-6.26M
26.27%-8.37M
32.87%-7.86M
-8.49%-7.43M
Basic earnings per share
69.09%-5.48
79.00%-0.5734
76.00%-1.2
53.85%-2.4
48.00%-2.6
46.27%-17.73
58.64%-2.73
47.92%-5
50.00%-5.2
19.35%-5
Diluted earnings per share
69.09%-5.48
79.00%-0.5734
76.00%-1.2
53.85%-2.4
48.00%-2.6
46.27%-17.73
58.64%-2.73
47.92%-5
50.00%-5.2
19.35%-5
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense -34.41%20.2M-43.37%3.56M-52.38%4.03M-25.30%6.07M-17.47%6.54M-22.04%30.8M-34.67%6.28M-26.82%8.46M-28.28%8.13M13.42%7.92M
Selling and administrative expenses 7.60%8.49M13.48%1.82M18.34%1.9M-7.74%2.35M13.39%2.42M-2.38%7.89M6.05%1.6M-19.46%1.6M-17.34%2.55M42.50%2.14M
-General and administrative expense 7.60%8.49M13.48%1.82M18.34%1.9M-7.74%2.35M13.39%2.42M-2.38%7.89M6.05%1.6M-19.46%1.6M-17.34%2.55M42.50%2.14M
Research and development costs -48.89%11.71M-62.85%1.74M-68.92%2.13M-33.30%3.72M-28.88%4.11M-27.09%22.91M-42.26%4.68M-28.35%6.86M-32.36%5.58M5.47%5.78M
Operating profit 34.41%-20.2M43.37%-3.56M52.38%-4.03M25.30%-6.07M17.47%-6.54M22.04%-30.8M34.67%-6.28M26.82%-8.46M28.28%-8.13M-13.42%-7.92M
Net non-operating interest income expense -13.10%297.97K248.76%148.93K17.45%56.5K-78.11%18.05K-56.08%74.49K-5.98%342.87K-1.26%42.7K-43.98%48.1K-8.71%82.46K21.71%169.61K
Non-operating interest income -13.84%311.37K202.26%143.31K11.00%59.1K-73.92%22.85K-50.25%86.11K-9.30%361.37K-16.17%47.41K-41.97%53.25K-15.01%87.61K17.74%173.1K
Non-operating interest expense -27.55%13.4K-219.30%-5.62K-49.38%2.61K-6.91%4.8K233.24%11.62K-45.15%18.5K-64.61%4.71K-12.79%5.15K-59.61%5.15K-54.45%3.49K
Other net income (expense) -89.93%56.05K452.92%45.32K-171.12%-34.59K-95.23%9.28K-88.95%36.05K630.52%556.73K-105.94%-12.84K-66.29%48.63K142.67%194.65K9,787.74%326.28K
Gain on sale of security -87.60%89.01K500.02%44.51K-138.46%-27.82K-94.44%11.13K-86.59%61.19K400.00%717.65K-116.67%-11.13K-48.00%72.32K143.90%200.27K4,000.10%456.18K
Other non- operating income (expenses) 79.52%-32.96K147.20%80971.40%-6.77K67.09%-1.85K80.64%-25.15K-219.84%-160.92K-101.15%-1.71K-556.05%-23.69K-29,484.21%-5.62K-796.19%-129.89K
Income before tax 33.62%-19.85M46.20%-3.36M52.09%-4.01M23.01%-6.05M13.45%-6.43M23.81%-29.9M33.17%-6.25M26.19%-8.37M32.89%-7.85M-8.43%-7.43M
Income tax -3.20%18.89K-39.11%2.88K2.84K7.70%7.95K-29.52%5.21K15.13%19.51K203.30%4.73K014.75%7.39K148.35%7.4K
Net income 33.60%-19.86M46.20%-3.37M52.06%-4.01M22.98%-6.05M13.46%-6.43M23.79%-29.92M33.09%-6.26M26.27%-8.37M32.87%-7.86M-8.49%-7.43M
Net income continuous Operations 33.60%-19.86M46.20%-3.37M52.06%-4.01M22.98%-6.05M13.46%-6.43M23.79%-29.92M33.09%-6.26M26.27%-8.37M32.87%-7.86M-8.49%-7.43M
Minority interest income
Net income attributable to the parent company 33.60%-19.86M46.20%-3.37M52.06%-4.01M22.98%-6.05M13.46%-6.43M23.79%-29.92M33.09%-6.26M26.27%-8.37M32.87%-7.86M-8.49%-7.43M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 33.60%-19.86M46.20%-3.37M52.06%-4.01M22.98%-6.05M13.46%-6.43M23.79%-29.92M33.09%-6.26M26.27%-8.37M32.87%-7.86M-8.49%-7.43M
Basic earnings per share 69.09%-5.4879.00%-0.573476.00%-1.253.85%-2.448.00%-2.646.27%-17.7358.64%-2.7347.92%-550.00%-5.219.35%-5
Diluted earnings per share 69.09%-5.4879.00%-0.573476.00%-1.253.85%-2.448.00%-2.646.27%-17.7358.64%-2.7347.92%-550.00%-5.219.35%-5
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion with Explanatory Notes--------Unqualified Opinion with Explanatory Notes--------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +14.09%
Sample Name
Sample Code
 +3.93%
Sample Name
Sample Code
 +2.06%
4
United States Oil Fund LP
USO
-1.12%
5
United States Gasoline Fund Lp
UGA
-2.10%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +22.28%
Sample Name
Sample Code
 +20.52%
Sample Name
Sample Code
 +19.71%
4
Zai Lab
ZLAB
+16.97%
5
Legend Biotech
LEGN
+16.57%
View More
Middle East conflict spreads to the stock market! How should investors respond?
Lebanon and Israel will implement a 10-day ceasefire! Iran's foreign minister, based on the Lebanon ceasefire agreement, announced the compl Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -